News

Published on 20 Jun 2023 on Benzinga via Yahoo Finance

Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In...

Article preview image

Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido, a topical treatment comprising lidocaine and halobetasol for hemorrhoid relief, significantly reduced symptom severity compared to individual components alone in Phase 2b trial.

Read the rest of the article
NASDAQ.CTXR price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Cit...

TipRanks · via Yahoo Finance 30 Dec 2024
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its...

Simply Wall St. · via Yahoo Finance 27 Dec 2024
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin...

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year Aft...

Benzinga · via Yahoo Finance 19 Aug 2024
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 11 Feb 2024
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 4 Sep 2023
Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In...

Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido, a topical treatment comprising lidocaine a...

Benzinga via Yahoo Finance 20 Jun 2023
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 27 Mar 2023
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc...

A downtrend has been apparent in Citius Pharmaceuticals, Inc. (CTXR) lately with too much selling...

Zacks via Yahoo Finance 28 Dec 2022
Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 18 Oct 2022
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ON...

Benzinga via Yahoo Finance 22 Sep 2022

Copyright Statfolio @ 2025

Social Accounts